Home
Search
Toolkit for Advocates

Toolkit for Advocates

We’ve made it easier for you to access information and share content about biotechnology and how it improves our daily lives, from prescription medications and a resilient food supply to renewable energy and sustainable bioprocessing materials. The information you discover can easily be shared on Twitter, Facebook and LinkedIn.

  • Show All
Results
  • Show All
PDF
Help Ensure Providers Have Access to All Approved Immunizations
FLIP
Provider choice means providers decide what immunization is best for their patients.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Help Ensure Providers Have Access to All Approved Immunizations
FLIP
Providers are best equipped to choose the right vaccine for their patients. Vaccines that prevent the same disease may have clinical, dosing, and/or presentation differences (e.g., fully-liquid or non-fully-liquid vaccines requiring reconstitution). Providers develop individual preferences based on their specialized knowledge and the specific healthcare needs of their patients.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Engaging in the Federal Rulemaking Process; How patient advocacy groups can get involved in the rulemaking process
FLIP
Learn how patient advocacy groups can get involved in the federal rulemaking process.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
The Orphan Cures Act
FLIP
The ORPHAN Cures Act is bipartisan legislation that would maintain existing incentives and boost research into new treatments for the 30 million Americans currently suffering from one of more than 7,000 rare diseases. The bill would achieve this by amending the Inflation Reduction Act’s harmful orphan drug exclusion and incentivizing critical follow-on investment into rare disease drug development.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Patient Benefits from 340B Have Eroded
FLIP
Congress created the 340B Drug Discount Program to help uninsured and vulnerable patients gain access to affordable prescription drugs and services. Over the years this program has expanded well past the original intent of Congress and now patients are not seeing the benefits they deserve.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
How DSH Hospitals Abuse the 340B Drug Pricing Program
FLIP
How DSH Hospitals Abuse the 340B Drug Pricing Program
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
340B Backgrounder
FLIP
In 1992, with the support of the biopharmaceutical industry, Congress created the 340B Drug Pricing Program to help uninsured and vulnerable patients. As part of the law, drug manufacturers provide significant discounts on outpatient medicines and treatments to select eligible health care “covered entities” — often referred to as safety- net providers.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Use of Human Cell Lines in Critical Vaccines and Therapies
FLIP
To develop a vaccine that can be produced on a large scale, researchers must grow viruses or bacteria in large quantities and with great consistency.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Vaccine Development, Licensure & Safety
FLIP
The creation of a vaccine involves scientists and medical experts from around the world, and it usually requires 10 to 15 years of research before the vaccine is made available to the general public.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Value of Vaccines: A Landmark Achievement
FLIP
Vaccination is often cited among the 10 greatest public health achievements of the 20th century. Only access to safe and clean water has had a larger effect on human health by preventing disease and extending lifespans.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
The U.S. Bioscience Industry Fosters Innovation and Drives America’s Economy Forward
FLIP
The bioscience industry and its supporting ecosystem drive bold innovations to address unmet human needs in the U.S. and around the world, including developing new breakthrough therapies that treat deadly diseases. The collective efforts of the industry and our public and private stakeholders have met the challenges of the COVID pandemic head-on, while lessening the impacts of climate change and nourishing a growing global population.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA Drug Negotiation: At a Glance
FLIP
Maximum Fair Price: A manufacturer of a drug selected for negotiation will be required to offer a “maximum fair price” for the selected drug with respect to Medicare beneficiaries.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Inflation Reduction Act – Medicare Part D Redesign/ Patient Out-Of-Pocket Cap
FLIP
The IRA restructures the Medicare Part D benefit to provide financial protections for beneficiaries and changes the contribution structure for plans, the government, and manufacturers.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA - Medicare Part D and ‘Smoothing’ of OOP Costs/MPPP
FLIP
Currently, millions of Medicare beneficiaries reach the catastrophic phase in January or February, which exacerbates the financial hardship of the high prices of OOP costs. The Inflation Reduction Act (IRA) will allow Medicare beneficiaries to spread their out-of-pocket cost over the course of the plan year.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA Medicare Inflation Rebates: At A Glance
FLIP
The Inflation Reduction Act (IRA) of 2022 requires biopharmaceutical companies to pay rebates to the government if the price for drugs in Medicare Part B or Part D increase faster than the rate of inflation.
DOWNLOAD PDF
VIEW PDF
FLIP
Solutions to Plastic Pollution
Play
Nov 23, 2022
YouTube
Solutions to Plastic Pollution
FLIP
Nov 23, 2022
Plastic is polluting our waterways and oceans, but biotechnology may deliver solutions. Plant-based bioplastics that can break down in months are one solution.
PLAY VIDEO
FLIP
PDF
Advanced/Innovative Manufacturing 101
FLIP
Our members are pioneering research into new breakthroughs, but an R&D amortization provision from the '17 Tax Cuts & Jobs Act that just went into effect will negatively impact this work.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Advanced/Innovative Manufacturing 101
FLIP
Learn more about Advanced/Innovative Manufacturing and its importance to biotech development.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Leveraging V3 for Digitally Derived Endpoints Framework - V3 as Applied to DHTTs Used in Various Drug Development Scenarios
FLIP
Leveraging V3 for Digitally Derived Endpoints Framework - V3 as Applied to DHTTs Used in Various Drug Development Scenarios
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Private Sector's Critical Role in Biomedical Innovation
FLIP
There is a misguided perception that NIH funding, not private market investment, is largely responsible for the creation and approval of new therapies. A new study by Vital Transformation¹ tests that hypothesis by tracking more than 20,000 patents linked to NIH grant over a 20 year period, identifying those associated with clinical trials and approved medicines, and quantifying the public and private investments made for those investigational and approved medicines.
DOWNLOAD PDF
VIEW PDF
FLIP